Overall survival with daratumumab, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (MAIA): a randomised, open-label, phase 3 trial

This is an accepted manuscript of an article published by Elsevier in The Lancet Oncology (in press). The accepted version of the publication may differ from the final published version.